News & Updates
Filter by Specialty:
Empagliflozin beneficial and well tolerated in acute heart failure
Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.
Empagliflozin beneficial and well tolerated in acute heart failure
06 Dec 2021
Overeating a marker of poor mental health, adverse outcomes among teens with diabetes
Overeating or binge eating symptoms are linked to lower quality of life, higher prevalence of depression and anxiety, and poor clinical outcomes among adolescents with type 1 diabetes, according to a study.
Overeating a marker of poor mental health, adverse outcomes among teens with diabetes
02 Dec 2021
Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor
The glucagon-like peptide-1 receptor agonist (GLP-1 RA) efpeglenatide affords cardiovascular and renal protection that is not explained by concurrent use of a sodium-glucose co-transporter-2 (SGLT2) inhibitor in patients with type 2 diabetes (T2D), according to an exploratory analysis of AMPLITUDE-O.
Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor
30 Nov 2021
Remnant cholesterol tied to CVD death in patients with T2D, CKD, diabetic nephropathy
Remnant cholesterol (C) appears predictive of mortality due to cardiovascular disease (CVD) among patients with type 2 diabetes (T2D), chronic kidney disease (CKD) stage 3 to 5, and incident diabetic nephropathy (DN), suggests a study.
Remnant cholesterol tied to CVD death in patients with T2D, CKD, diabetic nephropathy
29 Nov 2021
Insulin secretion predicts response to therapy in new-onset diabetes
The increase in C-peptide (C-Pep) above fasting following glucose load is associated with response to antihyperglycaemic therapy in patients with new-onset type 2 diabetes mellitus (T2DM), according to a study. The plasma C-Pep concentration ratio (C-Pep120/C-Pep0) may be used for the individualization of such therapy in this population.
Insulin secretion predicts response to therapy in new-onset diabetes
29 Nov 2021
Which amino acids are associated with cardiovascular events?
A recent study has recognized alanine and glutamine as new amino acids that appear to increase the risk of coronary artery disease (CAD) and reduce the hazard of ischaemic stroke, respectively.